- Trials with a EudraCT protocol (20)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (4)
20 result(s) found for: Fibrate.
Displaying page 1 of 1.
EudraCT Number: 2005-005698-31 | Sponsor Protocol Number: 4/2005 | Start Date*: 2006-09-12 |
Sponsor Name:National Medical Center (Országos Gyógyintézeti Központ) | ||
Full Title: Efficacy of fenofibrate treatment on the insulin sensitivity and pancreas ß-cell function in obese patients with hypertriglyceridemia. | ||
Medical condition: Patients non-diabetic, obese with hypertriglyceridemia (previously untreated with fibrate). | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: HU (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-002516-26 | Sponsor Protocol Number: 0524-063 | Start Date*: 2007-07-30 | |||||||||||
Sponsor Name:Merck, Sharp & Dohme Ireland (Human Health) Limited | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, “Crossover” Design Study to Evaluate the Lipid-Altering Efficacy and Safety of MK-0524B Combination Tablet Compared to MK 0524A + Simvastatin Coadministrati... | |||||||||||||
Medical condition: Hypercholesterolemia and Mixed Dyslipidemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) FR (Completed) SE (Completed) LT (Completed) DE (Completed) HU (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004448-60 | Sponsor Protocol Number: 0653A-128 | Start Date*: 2007-11-13 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Parallel Arm, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Elderly Patients With Hyp... | |||||||||||||
Medical condition: Hypercholesterolemia | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) IE (Completed) FI (Completed) BE (Completed) DK (Completed) DE (Completed) IT (Completed) AT (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001205-27 | Sponsor Protocol Number: ABR35884 | Start Date*: 2011-08-04 | |||||||||||||||||||||
Sponsor Name: | |||||||||||||||||||||||
Full Title: The effect of fibrate therapy in two patients with neutral lipid storage disease with myopathy (NLSDM). | |||||||||||||||||||||||
Medical condition: Neutral lipid storage disease with myopathy | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: | Gender: | ||||||||||||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002902-74 | Sponsor Protocol Number: EML 017008-004 | Start Date*: 2006-07-21 |
Sponsor Name:Merck Santé s.a.s. | ||
Full Title: A double-blind, double-dummy, randomized, controlled, multi-centre study of the activity and safety of 2 daily doses of EMD 387008 versus placebo and metformin in parallel groups after 8 weeks of t... | ||
Medical condition: Phase II study on type 2 diabetic subjects | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: LV (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-001234-18 | Sponsor Protocol Number: NA | Start Date*: 2019-03-06 |
Sponsor Name:Imperial College NHS Trust | ||
Full Title: Effect of EVOlocumab on CARotid plaque composition in asymptomatic carotid artery stenosis (EVOCAR-1) | ||
Medical condition: Carotid stenosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2011-001007-12 | Sponsor Protocol Number: MK-0524B-143 | Start Date*: 2011-07-29 | ||||||||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | ||||||||||||||||||
Full Title: A Phase III Multicenter, Double-Blind, Crossover Design Study to Evaluate Lipid-Altering Efficacy and Safety of 1 g/10 mg Extended-Release Niacin/Laropiprant/Simvastatin Combination Tablets in Pati... | ||||||||||||||||||
Medical condition: Primary Hypercholesterolemia & Mixed Dyslipdemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) LT (Prematurely Ended) NL (Prematurely Ended) LV (Prematurely Ended) CZ (Prematurely Ended) NO (Prematurely Ended) SK (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-001731-28 | Sponsor Protocol Number: C LF 23-0121 0401 | Start Date*: 2004-09-24 |
Sponsor Name:FOURNIER Laboratories Ireland | ||
Full Title: A double-blind, 3-arm study on weight loss with combination of micronised fenofibrate 267 mg and metformin 1700 mg per day compared to metformin 1700 mg and placebo, at 6 months, in obese patients,... | ||
Medical condition: Obesity | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-001921-86 | Sponsor Protocol Number: S185.4.001 | Start Date*: 2007-07-19 | |||||||||||
Sponsor Name:Solvay Pharmaceuticals GmbH | |||||||||||||
Full Title: A double-blind, placebo-controlled, parallel-group, multi-center study to investigate the effect of Omacor (n-3 PUFA) on lipid parameters in HIV infected patients treated with HAART | |||||||||||||
Medical condition: HAART-induced hypertriglyeridemia in HIV infected subjects | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003434-93 | Sponsor Protocol Number: ISIS-304801-CS16 | Start Date*: 2015-01-07 | |||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients with Hypertriglyceridemia | |||||||||||||
Medical condition: Hypertriglyceridemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Ongoing) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-003908-61 | Sponsor Protocol Number: Vasc-UMCU-10B | Start Date*: 2008-12-09 | |||||||||||
Sponsor Name:University Medical Center Utrecht | |||||||||||||
Full Title: A MULTICENTER, DOUBLE-BLIND, RANDOMIZED, 2-PERIOD, CROSSOVER STUDY TO COMPARE THE EFFECTS OF EZETIMIBE/SIMVASTATIN (10 MG/10 MG) COMBINATION TABLET VERSUS SIMVASTATIN 80 MG TABLET ON POSTPRANDIAL A... | |||||||||||||
Medical condition: Metabolic syndrome as defined by the ATP III criteria | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023939-42 | Sponsor Protocol Number: MK-0524B-118 | Start Date*: 2011-05-18 | ||||||||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | ||||||||||||||||||
Full Title: A Phase III Multicenter, Double-Blind, Crossover Design Study to Evaluate Lipid-Altering Efficacy and Safety of Extended-Release Niacin/Laropiprant/Simvastatin Combination Tablet in Patients with P... | ||||||||||||||||||
Medical condition: Primary Hypercholesterolemia & Mixed Dyslipdemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Completed) DE (Prematurely Ended) BG (Prematurely Ended) ES (Completed) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-001064-37 | Sponsor Protocol Number: S348.2.001 | Start Date*: 2008-07-31 | |||||||||||
Sponsor Name:Fournier Laboratories Ireland | |||||||||||||
Full Title: Effect of Choline Fenofibrate (ABT-335 /SLV348) on Macular Edema Measured by Optical Coherence Tomography in Subjects with Diabetic Macular Edema - a one-year, Placebo-Controlled, Randomized Study | |||||||||||||
Medical condition: Diabetic macular edema | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) CZ (Completed) NL (Completed) GB (Completed) ES (Completed) HU (Completed) AT (Prematurely Ended) DK (Completed) IT (Completed) BG (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006704-27 | Sponsor Protocol Number: Bezafibrate | Start Date*: 2009-07-17 | |||||||||||
Sponsor Name:Neuromuscular Research Unit, Copenhagen University Hospital Rigshopspitalet | |||||||||||||
Full Title: Effect of Bezafibrate on muscle metabolism during exercise in patients with fat metabolic disorders in skeletal muscle | |||||||||||||
Medical condition: Evaluation of the effect of Bezafibrate on muscle metabolism during exercise in patients with VLCAD and CPT II deficiency | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002526-25 | Sponsor Protocol Number: EP-547-201 | Start Date*: 2023-02-22 | |||||||||||
Sponsor Name:Escient Pharmaceuticals, Inc. | |||||||||||||
Full Title: Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP547 in Subjects with Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis | |||||||||||||
Medical condition: Subjects with Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000767-23 | Sponsor Protocol Number: D7990C00003 | Start Date*: 2020-11-12 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Randomized, Parallel, Double-blind, Placebo-controlled, Dose-ranging, Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD8233 Treatment in Participants With Dyslipidemia | |||||||||||||
Medical condition: Dyslipidemia, especially: evaluation of low-density lipoprotein cholesterol reduction at steady state at different doses of AZD8233 in order to select a therapeutic dose. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010198-19 | Sponsor Protocol Number: CLCQ908A2204 | Start Date*: 2009-05-27 | ||||||||||||||||
Sponsor Name:Novartis Pharma Services AG | ||||||||||||||||||
Full Title: A Phase 2 12-week multi-center, randomized, double-blind, placebo-controlled, parallel-group adaptive design study to evaluate the safety and efficacy of LCQ for weight reduction and reduced LDL ch... | ||||||||||||||||||
Medical condition: Obesity and mixed dyslipidemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Prematurely Ended) GB (Completed) ES (Completed) DK (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-000508-24 | Sponsor Protocol Number: 7406 | Start Date*: 2015-06-12 | |||||||||||
Sponsor Name:Newcastle Upon Tyne Hospitals NHS Trust | |||||||||||||
Full Title: A Feasibility Study of Bezafibrate in Mitochondrial Myopathy | |||||||||||||
Medical condition: Mitochondrial myopathy due to mt.3243A>G mutation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000641-13 | Sponsor Protocol Number: BIO89-100-221 | Start Date*: 2020-09-30 | |||||||||||
Sponsor Name:89bio, Inc. | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of BIO89-100 in Subjects with Severe Hypertriglyceridemia | |||||||||||||
Medical condition: Severe Hypertriglyceridemia (SHTG) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-005092-39 | Sponsor Protocol Number: TA-8995-304 | Start Date*: 2022-08-25 | ||||||||||||||||
Sponsor Name:NewAmsterdam Pharma BV | ||||||||||||||||||
Full Title: Obicetrapib and Cardiovascular Outcomes: A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular... | ||||||||||||||||||
Medical condition: atherosclerotic cardiovascular disease (ASCVD) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Trial now transitioned) IT (Ongoing) SK (Trial now transitioned) NL (Trial now transitioned) HU (Ongoing) BG (Ongoing) DK (Trial now transitioned) CZ (Trial now transitioned) FI (Trial now transitioned) LV (Ongoing) ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.